Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.

Andrea Casadei GardiniElisa ChiadiniLuca FaloppiGiorgia MarisiAngelo DelmonteMario ScartozziCristian LoretelliAlessandro LucchesiDevil OboldiAlessandra DubiniGiovanni Luca FrassinetiPaola Ulivi

Published in: BMC cancer (2016)

Results observed in this case encourage further research on the activity of sorafenib in both HCC and NSCLC, based on the presence of BRAF mutation. This could lead to a selection of HCC patients to be treated with this drug, and could help identify a novel treatment strategy for BRAF-mutated NSCLC patients.

Keyphrases

wild type
end stage renal disease
small cell lung cancer
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
emergency department
metastatic colorectal cancer
brain metastases
tyrosine kinase
adverse drug